Become IAPP Certified with updated AIGP exam questions and correct answers
You are the chief privacy officer of a medical research company that would like to collect and use sensitive
data about cancer patients, such as their names, addresses, race and ethnic origin, medical histories, insurance
claims, pharmaceutical prescriptions, eating and drinking habits and physical activity.
The company will use this sensitive data to build an Al algorithm that will spot common attributes that will
help predict if seemingly healthy people are more likely to get cancer. However, the company is unable to
obtain consent from enough patients to sufficiently collect the minimum data to train its model.
Which of the following solutions would most efficiently balance privacy concerns with the lack of available
data during the testing phase?
All of the following are included within the scope of post-deployment Al maintenance EXCEPT?
According to November 2023 White House Executive Order, which of the following best describes the
guidance given to governmental agencies on the use of generative Al as a workplace tool?
According to the GDPR's transparency principle, when an Al system processes personal data in automated
decision-making, controllers are required to provide data subjects specific information on?
What is the technique to remove the effects of improperly used data from an ML system?
© Copyrights DumpsCertify 2025. All Rights Reserved
We use cookies to ensure your best experience. So we hope you are happy to receive all cookies on the DumpsCertify.